Venus Concept extends bridge loan maturity and receives $2 million drawdown

Venus Concept Inc. (NASDAQ:VERO) announced Friday it entered into several financing agreements with lenders Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP. The company disclosed these developments in a statement based on a filing with the Securities and Exchange Commission.

According to the filing, Venus Concept and its subsidiaries signed a Consent Agreement that waives certain minimum liquidity requirements under an existing Main Street Priority Loan Agreement through November 30, 2025. The agreement also permits Venus Concept USA, Inc. to apply the November 8, 2025, cash interest payment due under each note to the outstanding principal balance of each note.

Additionally, Venus Concept and its subsidiaries entered into the Twenty First Bridge Loan Amendment Agreement with the same lenders. This amendment extends the maturity date of the company’s bridge loan from October 31, 2025, to November 30, 2025. It also waives specific minimum liquidity requirements under the bridge loan agreement through the same date.

The company reported a new loan drawdown as part of its ongoing bridge financing arrangements. On October 28, 2025, Venus Concept received a $2 million drawdown under its existing loan and security agreement. The company stated it expects to use the proceeds, after transaction expenses, for general working capital purposes.

The bridge financing facility, originally established on April 23, 2024, allows for term loans in multiple draws, with the total principal amount increased to $28,237,906.85. Borrowings under this facility bear interest at an annual rate of 12%. The company’s obligations are secured by a priority security interest in all real and personal property collateral of Venus Concept and its subsidiaries.

The information in this article is based on a press release statement and the company’s SEC filing.

In other recent news, Venus Concept Inc. reported its financial results for the second quarter of 2025, revealing a 5% decline in total revenue to $15.7 million compared to the previous year. The company also posted a net loss of $11.7 million, or $8.03 per share, with an adjusted EBITDA loss of $8.8 million. Despite these financial challenges, Venus Concept is pursuing strategic initiatives, including a planned product launch in early 2026 and exploring opportunities in the weight loss market. Additionally, the company secured a $2 million loan drawdown under its existing Loan and Security Agreement with Madryn Health Partners, bringing the total bridge financing to over $23 million. This loan bears an annual interest rate of 12% and is secured by a priority security interest in all collateral of the loan parties. Venus Concept also extended loan maturity and received waivers on certain liquidity requirements through September 30, 2025. These financial adjustments and strategic plans indicate the company’s efforts to navigate its current financial landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.